Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer
2026-07-24 20:30
•Justin Pope •The Motley Fool
•••••• •• Axe Capital view
Bristol Myers Squibb's Dividend: Solid for Now, but Watch the Horizon
BMY pays a reliable dividend today, but looming patent losses cast a shadow on future payouts.
Bristol Myers Squibb (BMY) offers a tempting 4.1% dividend yield, well-covered by current earnings and free cash flow—more than twice over. That’s a solid comfort zone, especially when dividend safety is a priority. But the landscape changes quickly in pharma. By 2028, BMY faces patent expiries on big sellers like Eliquis and Opdivo, risking nearly half its revenue falling to cheaper generic competition. For South African investors, this story mostly plays out through the USD/ZAR exchange rate, as BMY is dollar denominated. A weaker rand could cushion some pain, but currency volatility adds complexity. My view: this dividend is safe in the near term, but growth will likely slow. A steady 4% yield now might not hold in five years. Investors should watch for management’s strategy—whether they find new blockbuster drugs or pile on debt to sustain payouts. If they stumble, shares could slip despite the current comfort. this is just my opinion and not financial advice
I’d watch BMY for now, maybe buy modestly if you want steady income, but avoid chasing yield expecting growth. Keep an eye on USD/ZAR as it will affect returns for locals.
- BMY
- USD/ZAR
- Patent expiries leading to revenue loss
- Rand volatility impacting returns
6/10
Bristol Myers Squibb's 4.1% dividend yield is sustainable in the near term, with earnings and free cash flow covering the payout more than twice over. However, the company faces a significant patent cliff as key drugs like Eliquis and Opdivo lose exclusivity by 2028, threatening roughly half of total revenue. While the dividend appears safe for now, investors should monitor how management navigates these challenges, potentially through slower dividend growth.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Justin Pope
Categories: Rates, Equities, Earnings, Capital Returns, Financials, Healthcare
Tickers: BMY, CELGR
Sentiment: Neutral - The company demonstrates strong current dividend coverage and financial health, supporting a positive near-term outlook. However, significant patent expirations for major revenue-generating drugs (Eliquis and Opdivo) by 2028 create material long-term risks that offset optimism. The neutral rating reflects this balanced risk-reward profile with both supportive fundamentals and legitimate future headwinds.
Keywords: dividend yield, patent cliff, pharmaceutical, free cash flow, generic competition, drug patents
Insights:
- BMY: Neutral: The company demonstrates strong current dividend coverage and financial health, supporting a positive near-term outlook. However, significant patent expirations for major revenue-generating drugs (Eliquis and Opdivo) by 2028 create material long-term risks that offset optimism. The neutral rating reflects this balanced risk-reward profile with both supportive fundamentals and legitimate future headwinds.
- CELGR: Neutral: The company demonstrates strong current dividend coverage and financial health, supporting a positive near-term outlook. However, significant patent expirations for major revenue-generating drugs (Eliquis and Opdivo) by 2028 create material long-term risks that offset optimism. The neutral rating reflects this balanced risk-reward profile with both supportive fundamentals and legitimate future headwinds.